Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Pediatr Blood Cancer. 2020 Jun 26;67(9):e28530. doi: 10.1002/pbc.28530

Table 1.

Participant characteristics

Intervention (n=25) Waitlist (n=24)
M (SD) or n (%) M (SD) or n (%)
Current Age (years) 18.76 (3.9) 18.25 (3.6)
Sex
 Male 10 (40.0%) 15 (62.5%)
 Female 15 (60.0%) 9 (37.5%)
Cancer Diagnosis
 Blood Cancer 19 (76.0%) 21 (87.5%)
 Brain Tumor 3 (12.0%) 0 (0.0%)
 Solid Tumor 3 (12.0%) 3 (12.5%)
Age at diagnosis (years) range 7.36 (5.5) [0-17] 8.54 (6.1) [0-19]
Time since treatment completed (years) range 9.46 (5.5) [1-22] 7.63 (4.4) [1-16]
Treatment Received
Chemotherapy (yes) 25 (100%) 24 (100%)
Radiation
  Yes 7 (28.0%) 7 (29.2%)
  No 18 (72.0%) 17 (70.8%)
BMT/HSCT
  Yes 4 (16.0%) 3 (12.5%)
  No 21 (84.0%) 21 (87.5%)
Race/Ethnicity:
 Non-Hispanic White 13 (52.0%) 14 (58.3%)
 Non-Hispanic Black 1 (4.0%) 2 (8.3%)
 Non-Hispanic Asian 3 (12.0%) 4 (16.7%)
 More than 1 race 3 (12.0%) 1 (4.2%)
 Other/unknown 5 (20.0%) 4 (16.7%)
Employment Status:
 Student 19 (76.0%) 17 (70.8%)
 Part-Time 3 (12.0%) 4 (16.7%)
 Full-Time 2 (8.0%) 3 (12.5%)
 Unemployed 1 (4.0%) 0 (0.0%)
Health Insurance:
 None 0 (0.0%) 2 (8.3%)
 Public 7 (28.0%) 7 (29.2%)
 Private 18 (72.0%) 17 (70.8%)
Marital Status:
 Single, never married 24 (96.0%) 25 (100.0%)
 Married/Partnered 1 (4.0%) 0 (0.0%)

Note. BMT = Bone Marrow Transplant; HSCT = Hematopoietic Stem Cell Transplant